Scholars Central

Research articlePublished 2014

Resveratrol Enhances the Bioavailability of Fexofenadine in Healthy Human Male Volunteers: Involvement of P-Glycoprotein Inhibition

Authors: Satish Kumar Bedada, Sudhakar Akul Yakkanti, Prasad Neerati

Journal of Bioequivalence & Bioavailability

Volume 6 · Issue 5 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Objective: The purpose of the present study was to assess the influence ofresveratrol onP-glycoprotein mediated drug disposition in humans using fexofenadine as a P-glycoprotein substrate. Methods: A non-blinded, an open label crossover study was conducted in twelve healthy male volunteers aged between 26 and 31 years. A single dose of fexofenadine hydrochloride 120 mg was given to volunteers during control phase and treatment phases. A single dose of resveratrol 500 mg was given to volunteers once daily for period of 10 days. The blood samples were collected at predetermined time intervals during control and treatment phases. The plasma samples containing fexofenadine hydrochloridewere analyzed by LC-MS/MS. The pharmacokinetic parameters were computed by non-compartmental method and the mean pharmacokinetic parameter differences during control and treatment phases were assessed. Results: Treatment with resveratrol significantly increased thearea under the plasma concentration-time curve (AUC) and maximum plasma concentration (Cmax) offexofenadine to 76.7%(2520.92.48 versus 4454.48 ng.h/mL) and 65.2% (415.08 versus 685.58 ng/mL)respectively when compared to control phase. On other hand, apparentoral clearance (CL/F) and apparent volume of distribution (Vd/F) of fexofenadine were significantly decreased by 42.6% (49.46 versus 28.37 L/h) and 42.1 % (591.73 versus 342.62 L) respectively. However, there was no significant change was observed in T1/2, Kel and Tmaxof fexofenadine upon treatment with resveratrol when compared to control phase. Conclusion: The results of the present study showed that multiple doses of resveratrolenhanced the bioavailability of fexofenadine probably by the inhibition of P-glycoprotein mediated drug efflux in humans.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Bioequivalence & Bioavailability.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioequivalence & Bioavailability
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Satish Kumar Bedada”
  • BylineArticles whose byline prints “Sudhakar Akul Yakkanti”
  • BylineArticles whose byline prints “Prasad Neerati”